ADALIMUMAB
Generic: ADALIMUMAB-AATY
CELLTRION USAManufacturer
2023-05-23Original Approval
ADALIMUMAB is FDA application BLA761219, sponsored by CELLTRION. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Top Reported Reactions
1
DRUG INEFFECTIVE
10,427 reports
2
OFF LABEL USE
8,267 reports
3
RHEUMATOID ARTHRITIS
5,663 reports
4
FATIGUE
5,468 reports
5
PAIN
5,418 reports
6
ARTHRALGIA
5,168 reports
7
RASH
4,635 reports
8
CONDITION AGGRAVATED
4,475 reports
9
DRUG INTOLERANCE
4,253 reports
10
SYSTEMIC LUPUS ERYTHEMATOSUS
4,113 reports